TrialSignal
Clinical trial intelligence report
A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03986073-Jul 28, 2026
NCT ID
NCT03986073
Status
UNKNOWN
Phase
PHASE2
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Executive brief
Investment-Ready Snapshot
A Phase IIA , Multi-center, Randomized, Double-blind, Placebo and Positive Drug Parallel Control Study of TQ-F3083 Capsules With Different Doses in Subjects With Type 2 Diabetes Mellitus is a PHASE2 clinical asset sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in Type 2 Diabetes Mellitus. SEO and diligence focus: TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03986073
Indication
Type 2 Diabetes Mellitus
Modality
small molecule
Target
TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet
Intervention
TQ-F3083 capsule 10 mg, TQ-F3083 capsule 20 mg, TQ-F3083 blank analog capsule, TQ-F3083 blank analog capsule, Linagliptin blank analog tablet, Linagliptin tablet
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.